← Back to results
Federal

Saving Access to Laboratory Services Act

Source: Congress.gov  ·  2,400 words in original text
This bill modifies how Medicare pays for clinical diagnostic laboratory tests (blood tests and similar medical lab work). It allows the government to collect payment information from a sample of labs instead of all labs. The bill also changes payment reduction limits and adds caps on payment increases for these services.
Clinical diagnostic laboratories including independent labs, hospital labs, hospital outreach labs and physician office labs that perform diagnostic tests and receive Medicare payments. The Centers for Medicare and Medicaid Services (the federal agency that runs Medicare).
• Starting with data collection periods beginning January 1, 2026, the government can collect payment information from a statistically valid sample of labs instead of requiring all labs to report, but only for widely available clinical diagnostic laboratory tests (Sec. 2(a)(1)). • The government must use the maximal brewer selection method to develop this sampling methodology, with input from stakeholders, to make sure the sample accurately represents different types of labs and their payment rates (Sec. 2(a)(1)(C)(ii)(I) and (II)). • Labs with less than 10 percent of claims paid electronically during a data collection period can exclude manual payment information from what they report (Sec. 2(c)(2)). • Starting in 2024, payment decreases cannot exceed 0 percent for 2024, 2.5 percent for 2025, and 5 percent for 2026 and beyond (Sec. 2(d)(1)). • Starting in 2024, payment increases are capped at 2.5 percent annually for widely available tests through 2025, then 3.75 percent for 2026 and 2027, then 5 percent from 2028 forward (Sec. 2(d)(2)). • A "widely available clinical diagnostic laboratory test" is defined as a test that costs less than 1,000 dollars per test and is performed by more than 100 applicable laboratories (Sec. 2(a)(1)(C)(iii)).
The data collection timeline shifts to begin January 1, 2026, instead of the original January 1, 2024. Labs performing widely available tests will only need to provide data if selected for the government sample, rather than all labs reporting. The "applicable laboratory" definition changes to labs receiving at least 12,500 dollars in Medicare payments during the first 6 months of the calendar year before the data collection period, removing a previous requirement. The government must publish its list of widely available tests by September 30 of the year before each data collection period. Data collection frequency changes from every three years to every four years.
"Widely available clinical diagnostic laboratory test" means a test costing less than 1,000 dollars per test performed by more than 100 applicable laboratories during the first 6 months of the calendar year immediately before the data collection period (Sec. 2(a)(1)(C)(iii)). "Applicable laboratory" means a laboratory receiving at least 12,500 dollars in Medicare payments during the first 6 months of the calendar year before the data collection period (Sec. 2(b)). "Applicable information" includes data on what private insurance companies pay for these tests (Sec. 2(c)).
The bill's data collection provisions take effect beginning January 1, 2026. The government must implement these changes through official rulemaking procedures no later than December 31, 2024 (Sec. 2(e)).
Important: This plain English summary was generated by AI and is provided for informational purposes only. It is not legal advice. Always consult the official bill text on Congress.gov or a qualified attorney for legal matters.